Please select the option that best describes you:
What gemtuzumab regimen and schedule (with standard 7 plus 3) would you use for a newly diagnosed AML patient with favorable genetics?
Answer from: Medical Oncologist at Academic Institution
Per the ALFA-0701 trial, we administer GO (3 mg/m2, capped at 4.5 mg vial) on days 1,4, and 7 of induction therapy with 7+3.
Sign In or Register to read more